Table 1 Characteristics of reports associated with Lanreotide and octreotide from Q1 of 2004 to Q2 of 2024.
Variable | Lanreotide (%) | Octreotide (%) |
|---|---|---|
Gender | ||
Female | 4040(52.68) | 9291(49.25) |
Male | 3318(43.27) | 7781(41.25) |
Unknown | 311( 4.06) | 1792( 9.50) |
Age | ||
<18 | 41( 0.53) | 254( 1.35) |
18 ~ 25 | 50( 0.65) | 68( 0.36) |
25 ~ 60 | 2255(29.40) | 3583(18.99) |
>=60 | 2729(35.58) | 6486(34.38) |
Unknow | 2594(33.82) | 8473(44.92) |
Outcomes | ||
Other serious | 3020(49.37) | 9302(44.51) |
Hospitalization | 1842(30.11) | 6120(29.28) |
Death | 1046(17.10) | 4714(22.56) |
Disability | 122( 1.99) | 184( 0.88) |
Life threatening | 83( 1.36) | 549( 2.63) |
Congenital anomaly | 3( 0.05) | 12( 0.06) |
Required intervention to Prevent Permanent Impairment/Damage | 1( 0.02) | 18( 0.09) |
Reported countries | Top 5 | |
United States | 4094(55.44) | 4172(23.01) |
United Kingdom | 861(11.66) | 1053( 5.81) |
Other | 794(10.75) | 7249(39.99) |
Canada | 749(10.14) | 3038(16.76) |
Netherlands | 339( 4.59) | 473( 2.61) |
